Hem-Onc Fellows Network

‼️Financial wellness starts before your first attending job‼️ Join Jimmy Turner, MD (@TPP_MD), founder of Money Meets Medicine, to discuss disability insurance and income protection for trainees. 🗓 Feb 17 | 6 PM EST 🔗(register) tinyurl.com/HOFN-Financial… Host @KalantriShreyas

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial buff.ly/uLdWEf5 In the phase III TROPION-Breast02 trial, datopotamab deruxtecan (Dato-DXd) significantly improved progression-free and overall survival versus chemotherapy in previously untreated advanced triple-negative #BreastCancer patients ineligible for immunotherapy. Objective response rates were higher and responses more durable with Dato-DXd. Safety was consistent with prior studies, with similar rates of serious adverse events but fewer treatment discontinuations compared with chemotherapy. @RebeccaDSing @JavierCortesMD @VukovicPetra @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @Onco_Cifu88

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905 trial results and Research Summary: nejm.org/doi/full/10.10…

TROPION-Breast02 published in @Annals_Oncology: 1L therapy with Dato-DXd led to near doubling of PFS, ORR and significant OS benefit (vs chemo) in IO-ineligible mTNBC. New important option and new hope for one of the most aggressive forms of breast cancer. annalsofoncology.org/article/S0923-…

Doctor, not provider. @ACPIMPhysicians @AnnalsofIM acpjournals.org/doi/10.7326/AN…

In the EdiThal study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat transfusion-dependent β-thalassemia. Full study results: nejm.org/doi/full/10.10… Editorial: More Options for Gene Editing in Hemoglobinopathies nejm.org/doi/full/10.10… Further reading: 📄 Original Article: Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease (BEACON study) nejm.org/doi/full/10.10… 📄 Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease (RUBY study) nejm.org/doi/full/10.10…

Starting to get ready for #ASCO26 Excited to be part of this year's @OncLive National Fellows Forum with @benlevylungdoc @StephenVLiu @PatelOncology @christine_lovly @drshieldsmd To the young PIs out there...submit an abstract & join us! @CancerCentreIre @RCSI_Irl @IrishCancerSoc #LCSM

📌 Onc (GU) Trials Tweetorial Series Germ Cell Tumor Index Thread: From the trial that cured a death sentence to the survivorship costs we still manage decades later. A series of threads tracing the evidence behind modern GCT care. 🧵 #OncTrials101 #GUTrials101 #GermCellTumor #GUsm #Medtwitter #OncTwitter @ASCO @UrologyTimes @OncoAlert @oncodaily @TCSociety @TestesCancer @HemOncFellows @IMG_Oncologists @ASCOTECAG @EurUrolOncol

Among men with #ProstateCancer undergoing hormone therapy, #SGLT2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit. ja.ma/47n2KQK

🚹 At #GU26, #prostatecancer updates pointed to a more personalized, tech-enabled future of patient care. @NehaVapiwala of @UniversityofP discusses sequencing strategies, radiopharmaceuticals, #AI, and survivorship priorities. 🎥 Watch the video: ascopost.com/videos/2026-as…

In an evaluation in low- and middle-income countries involving 95 patients with chronic myeloid leukemia who had deep remission for more than 1 year, 79% remained in treatment-free remission after imatinib discontinuation. Learn more: nejm.org/doi/full/10.10…

Original Article: Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer (phase 3 ATOMIC trial) nejm.org/media/doi/full… Editorial: ATOMIC Energy — Biomarker-Bespoke Adjuvant Therapy for Colon Cancer nejm.org/doi/full/10.10… #Oncology #Gastroenterology

Pearl: The same treatments that cure testicular cancer carry a measurable lifelong price : elevated cardiovascular risk beginning a decade after treatment, and a significantly increased risk of solid tumors persisting for at least 35 years. This is why de-escalation: smaller RT fields, fewer cycles, surveillance is not just convenience, It is a survivorship strategy. Meinardi et al. JCO 2000 | Huddart et al. JCO 2003 | Travis et al. JNCI 1997 | Travis et al. JNCI 2005 #OncTrials101 #GUTrials101 #GUSM #MedTwitter #OncTwitter @HemOncFellows 8/8

📌 Onc (GU) Trials Tweetorial Series Survivorship: The Cost of Cure | Meinardi 2000, Huddart 2003, Travis 1997 & 2005 Testicular cancer is one of oncology’s greatest success stories. But cure comes at a cost—one that unfolds over decades. 🧵1/8 #OncTrials101 #GUTrials101 #GermCellTumor #GUsm #Medtwitter #OncTwitter

Original Article: Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer nejm.org/doi/full/10.10… @myESMO | #ELCC26

Dreaming of San Diego this April? Submit your GynOnc research for a chance to win an all-expense-paid trip! ✈️ Round-trip airfare 🏨 1-night hotel stay 🤝 Elite networking We’re selecting 20 fellows—will you be one of them? Apply: hubs.li/Q047-B8t0

Want to present your data to top oncology experts? Submit your Lung Cancer abstract for the OncLive National Fellows Forum. If selected, your trip to Chicago on May 28 is fully covered. Build your network. Advance your career. Submit: hubs.li/Q046Wyj20 @benlevylungdoc @hopkinskimmel @StephenVLiu @Georgetown @MedStarGUH @LombardiCancer @drshieldsmd @TheShieldsLab @SclcSMASHERS @IndianaUniv @christine_lovly @CityofHope

We are #Hiring at @AdventHealthCFL #cancer Institute, Orlando, #Florida area! Looking for Genitourinary (GU) #cancer-focused medical Hematologist-Oncologist to also support the rapidly growing Phase I solid tumor #clinicaltrial program- especially suitable for a junior medical oncologist who is interested in a hybrid of #prostatecancer focused medical oncology practice + clinical trials (#research) and wants to develop an #earlydrugdevelopment career- and an opportunity to collaborate with world class urology and Radiation Oncology team - flexibly tailor the practice to fit career goals - @AdventHealthCFL was ranked as one of the top 20 hospitals by US News & World Report in 2025-and the among the top 50 in the nation for 6 medical specialties including #Cancer - we are the largest healthcare system in central Florida - and a teaching program with Internal Medicine residency - and will have a Hematology-Oncology fellowship in the near future adventhealthfloridaphysicianjobs.com/Physician_Job/…

Thank you @ecancer for highlighting this important work at GU @ASCO 2026 #GU2026 ecancer.org/en/video/12814…

1/n Now published in @NatureMedicine : The phase 2 #POLAR trial of pembrolizumab + olaparib maintenance in metastatic pancreatic cancer. @CpcrMsk @MSKCancerCenter @MSK_DeptOfMed @PICIatMSK rdcu.be/e9WmJ

The draft guideline protocol for "Treatment of Patients with Invasive #CervicalCancer" is open for comments. Please review and submit your comments by April 7 to help shape final recommendations. Learn more: bit.ly/3NCzuOW #gyncsm